How to Bet Big on a Biotech Rebound in 2017

Investors looking for a 2017 rebound in biotech stocks may get some help from relaxed regulation under the incoming Trump administration, says Sylvia Jablonski, managing director of capital markets for Direxion. Jablonski says the assumption of a Democratic victory in November sank the sector in 2016, but a reduction in regulations under President-Elect Trump should help it.